ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI with Median Overall Survival of 6.3 Months in Patients with Third-Line Disease, More than Doubling Historical Survival

Data show that ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine, is potentially effective in pancreatic cancer where very few treatment options exist Nant Cancer Vaccine therapy more than doubles median overall survival (OS) versus historical OS in...

ImmunityBio Announces Completion of $470 Million Post-Merger Financing to Fund Late-Stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing

Year-End Review: SISONKE Universal Boost COVID T-Cell vaccine trial initiates Phase 3 enrollment in South Africa in previously vaccinated participants Increased GMP manufacturing capacity for RNA, DNA, Subunit Proteins, and Adjuvants vaccine platforms in U.S., South...